MRNA vs NVST
Moderna vs Envista Holdings — AI-powered side-by-side comparison
VS
NVST
Envista Holdings
68
Buy
| Metric | MRNA | NVST |
|---|
| AI Score |
61
|
68
|
| Price |
$158.81
|
$27.47
|
| P/E Ratio |
-17.40×
|
46.34×
|
| ROE |
-32.6%
|
1.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
-12.6%
|
55.5%
|
| Debt / Equity |
0.19×
|
0.52×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
68.6
|
44.8
|
| Beta |
0.899
|
0.861
|
| Expected Upside |
—
|
+4.6%
|
AI Committee View
Current Innellis committee reasoning for MRNA versus NVST.
NVST leads by 7 points.
NVST scores 68/100 (Buy) versus MRNA at 61/100 (Buy).
MRNA Committee View
67% agreement
6 analysts
The primary driver is price structure making higher highs and higher lows. The main limiting factor is bollinger bandwidth of 194.9% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.3x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- ROE of only -39.2% -- cheap may mean cheap for a reason — Value
- Revenue declining -27.6% YoY -- this is not a growth story right now — Growth
- Weekly RSI at 82 -- overbought on the larger timeframe too — Technical
NVST Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is macd histogram negative -- bearish momentum. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical